Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by MrMugsy on May 04, 2021 9:03am

Mesalamine ...

Looks like Mesalamine was the active incredient used in the first Antibe IBD drug (ATB-429).
Guessing they were able to use a more efficient H2S carrier to create a new drug.
That bodes well for upgrading others in the future.

https://academic.oup.com/ibdjournal/article/13/suppl_5/645/4653174
Comment by Actuarial on May 04, 2021 9:32am
more evidences to confirm the H2S platform. This is great!
Comment by 123ABC on May 04, 2021 9:41am
It's so great that stock is red again
Comment by Harper75 on May 04, 2021 10:17am
Have you seen the market today?
Comment by MrMugsy on May 04, 2021 10:18am
As ugly as the weather here. : )
Comment by MasterAlgae on May 04, 2021 9:57am
It is evidence that they are no longer using that drug as a base. The findings were published almost to the day, 14 years ago. It was Published: 01 May 2007.
Comment by MrMugsy on May 04, 2021 10:13am
No MasterAlgae. They are using that drug now - Dan just mentioned the drug in the last (or second last) video presentation.  That's why I searched it up.  I didn't realize it was also part of the old ATB-429. Hence, making what was old ... new again. New patents. Afterall ... that is one of the paths they are going down w.r.t. the academic studies ... finding more efficient ...more  
Comment by MasterAlgae on May 04, 2021 10:15am
My bad. Thanks for the clarification.
Comment by MrMugsy on May 04, 2021 10:24am
So ... really what I'm getting at is ... the same academic study is underway for 340. Find a more efficient carrier to replace 340 and create a new patent. Then you have hope for IP protection (IP lead) farther into the future. OTENA doesn't need to have a patent cliff in 2030/32 if we create a follow-on drug (again - the follow-on ideas was used by Dan in a conference call). That ...more  
Comment by Duster340 on May 04, 2021 10:52am
Duster340 Writes:  this guy's opinion changes depending on what is going on with the stock, not to long ago when ate was over $7 he was saying big pharma was knocking on the door, could happen anytime.  now your opinion has changed to stay in tune with the current stock price. hahaha thats funny.. the reason we are down is because of p3 delay's and also the length of the trials ...more  
Comment by 123ABC on May 04, 2021 11:01am
  Well, he's gotta pass the time while getting paid to pump. Wonder where his pumper buddy Crow is
Comment by Fotoforester on May 04, 2021 11:12am
When you have a significant amount of capital invested in something you don't need to be paid. You'll praise it for free and also do your research.
Comment by Stoxxhp on May 04, 2021 11:13am
This post has been removed in accordance with Community Policy
Comment by 123ABC on May 04, 2021 11:29am
I am getting paid right now but not by Antibe
Comment by 3burtc on May 04, 2021 12:10pm
You know I couldn't agree more that improving patent protection is an excellent idea but disagree on the importance of it. My reasoning is that Otenaproxesul should get 50 % of the market for unmet needs. Now, Dan finally admitted that peak sales will be around $8 billion usd when lower back pain is included and if you take into consideration that they can force well know brands of the market, ...more  
Comment by WalkOverTheStrt on May 04, 2021 1:15pm
$6B for all of it sounds about right :) 
Comment by Harper75 on May 04, 2021 1:43pm
That would truly be the happiest of endings for this saga
Comment by Layth1990 on May 04, 2021 1:48pm
can you stop dreaming and be realistic for a second ?  that is 14 years old article...  price almost same as ipo decade ago. management need to be productive, all this will not really help. only a series of good news will change how investors think about ate.  most people took their money out.... God knows when we will see green again 
Comment by 3burtc on May 04, 2021 2:00pm
Don't care about short term. Ten years of free cashflow makes Ate a 9 billion dollar company.
Comment by Actuarial on May 04, 2021 2:08pm
I am okay with a 3-billion bought out deal if it happens sooner.
Comment by 3burtc on May 04, 2021 2:29pm
Don't get me wrong I do believe big pharma should take ate out for about 9 billion but I think what happens first is an equal merger between knight and Ate. I've seen too many signals from the Market maker that tells me a deal is on its way.
Comment by Actuarial on May 04, 2021 2:05pm
Hi Layth1990, you need to check Mesalamine patent expiry date first before you question why ATE didn't start clinical trial 14 years ago.
Comment by MrMugsy on May 04, 2021 2:15pm
Layth ... you're not following. It's a good thing the article is old and the new drug is the same old active product. From an IP perspective - that's exactly what you want. You figure out the rest. Try not to be so salty and open your mind a little - I know others can infect ... but don't let it. : )
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities